IM Ketamine vs Midazolam for Suicidal ER Patients
Principal Investigator: Michael Grunebaum, MD
The goal of this study is to examine how effective the experimental antidepressant ketamine is for reducing suicidal thoughts and depressive symptoms. The study recruits participants in the New York-Presbyterian/Columbia Comprehensive Psychiatric Emergency Program (CPEP). After clinical assessments, participants receive a single intramuscular injection of ketamine or the comparison medication midazolam and after are admitted for inpatient treatment. Follow up assessments occur for the duration of the inpatient stay and four weeks after discharge.